Among the 54 established PDX models, 12 were developed from FGFR-driven tumours resistant to erdafitinib, 9 from EGFR-mutant osimertinib resistant tumours and 4 from ALK-rearranged lung cancers resistant to lorlatinib (Fig. 2b, c). Here, EGFR is linked to neoplasm.